BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3

• US 20170114135A1
• Filed: 09/29/2016
• Published: 04/27/2017
• Est. Priority Date: 10/02/2015
• Status: Active Grant

• Current Assignee: F Hoffmann-La Roche AG (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: CODARRI-DEAK, LAURA, FISCHER, JENS, LIFKE, VALERIA, PERRO, MARIO, REGULA, JOERG THOMAS, WUENSCHE, ILDIKO, ZWICK, ADRIAN, FERTIG, GEORG, KLEIN, CHRISTIAN, LEVITSKI, VIKTOR, SCHLOTHAUER, TILMAN, SEEBER, STEFAN, UMANA, PABLO
• Granted Patent: US 10,287,352 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/51 Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/515 Complete light chain, i.e. VL + CL
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/66 comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
• CPC Class Codes: C07K 2317/71 Decreased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/77 : Internalization into the cell
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Claims

1. A bispecific antibody comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, wherein

said first antigen-binding site specifically binding to PD1 comprises

a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:

37,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

38, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO;

39; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

40;

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

41, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

42; and

said second antigen-binding site specifically binding to TIM3 comprises

(a) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

1,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

2, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO;

3; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

4 or SEQ ID NO;

11 or SEQ ID NO;

12,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

5, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

6;

or

(b) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

17,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

18, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO;

19; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

20,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

21, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

22;

or

(c) a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO;

29,

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO;

30, and

(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO;

31; and

a VL domain comprising

(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO;

32,

(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO;

33, and

(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO;

34.

2. The bispecific antibody of claim 1, wherein the bispecific antibody binds to TIM3 with an at least 50-fold lower binding affinity when compared to the binding to PD1.

3. The bispecific antibody according to claim 1, wherein

said first antigen-binding site specifically binding to PD1 comprises

(a) a VH domain comprising the amino acid sequence of SEQ ID NO:

43 and a VL domain comprising the amino acid sequence of SEQ ID NO;

44, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO;

45 and a VL domain comprising the amino acid sequence of SEQ ID NO;

46, or

(c) a VH domain comprising the amino acid sequence of SEQ ID NO;

45 and a VL domain comprising the amino acid sequence of SEQ ID NO;

47, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO;

45 and a VL domain comprising the amino acid sequence of SEQ ID NO;

48, or

(e) a VH domain comprising the amino acid sequence of SEQ ID NO;

45 and a VL domain comprising the amino acid sequence of SEQ ID NO;

49,

and said second antigen-binding site specifically binding to TIM3 comprises

(a) a VH domain comprising the amino acid sequence of SEQ ID NO;

7 and a VL domain comprising the amino acid sequence of SEQ ID NO;

8, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO;

9 and a VL domain comprising the amino acid sequence of SEQ ID NO;

10, or

(c) a VH domain comprising the amino acid sequence of SEQ ID NO;

13 and a VL domain comprising the amino acid sequence of SEQ ID NO;

14, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO;

15 and a VL domain comprising the amino acid sequence of SEQ ID NO;

16, or

(e) a VH domain comprising the amino acid sequence of SEQ ID NO;

23 and a VL domain comprising the amino acid sequence of SEQ ID NO;

24, or

(f) a VH domain comprising the amino acid sequence of SEQ ID NO;

25 and a VL domain comprising the amino acid sequence of SEQ ID NO;

26, or

(g) a VH domain comprising the amino acid sequence of SEQ ID NO;

27 and a VL domain comprising the amino acid sequence of SEQ ID NO;

28, or

(h) a VH domain comprising the amino acid sequence of SEQ ID NO;

35 and a VL domain comprising the amino acid sequence of SEQ ID NO;

36.

4. The bispecific antibody according to claim 1, wherein

said first antigen-binding site specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO:

45 and a VL domain comprising the amino acid sequence of SEQ ID NO;

46,

and said second antigen-binding site specifically binding to TIM3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO;

15 and a VL domain comprising the amino acid sequence of SEQ ID NO;

16 or a VH domain comprising the amino acid sequence of SEQ ID NO;

25 and a VL domain comprising the amino acid sequence of SEQ ID NO;

26.

5. The bispecific antibody according to claim 1, wherein

said first antigen-binding site specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO:

45 and a VL domain comprising the amino acid sequence of SEQ ID NO;

46, and

said second antigen-binding site specifically binding to TIM3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO;

25 and a VL domain comprising the amino acid sequence of SEQ ID NO;

26.

6. The bispecific antibody according to claim 1, wherein the bispecific antibody is a human, humanized or chimeric antibody.

7. The bispecific antibody of claim 1, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen-binding site that specifically binds to PD1 and a second Fab fragment comprising the antigen-binding site that specifically binds to TIM3.

8. The bispecific antibody of claim 7, wherein the Fc domain is an IgG1 Fc domain or an IgG4 Fc domain.

9. The bispecific antibody of claim 7, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ

receptor.

10. The bispecific antibody of claim 7, wherein the Fc domain is of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

11. The bispecific antibody of claim 7, wherein the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.

12. The bispecific antibody of claim 7, wherein a first subunit of the Fc domain comprises knobs and a second subunit of the Fc domain comprises holes according to the knobs into holes method.

13. The bispecific antibody of claim 7, wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

14. The bispecific antibody of claim 7, wherein in one of the Fab fragments the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain.

15. The bispecific antibody of claim 14, wherein in the first Fab fragment comprising the antigen-binding site that specifically binds to PD1 the variable domains VL and VH are replaced by each other.

16. The bispecific antibody of claim 7, wherein in one of the Fab fragments in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

17. The bispecific antibody of claim 16, wherein in the second Fab fragment comprising the antigen-binding site that specifically binds to TIM3 the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

18. The bispecific antibody of claim 1, comprising

(a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:

50, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

52,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

51, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

53, or

(b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

54, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

56,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

55, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

57, or

(c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

58, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

60,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

59, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

61, or

(d) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

62, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

64,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

63, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

65, or

(e) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

66, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

68,

a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

67, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO;

69.

19. The bispecific antibody of claim 1, comprising

(a) a first heavy chain comprising the amino acid sequence of SEQ ID NO:

50, a first light chain comprising the amino acid sequence of SEQ ID NO;

52,

a second heavy chain comprising the amino acid sequence of SEQ ID NO;

51, and a second light chain comprising the amino acid sequence of SEQ ID NO;

53, or

(b) a first heavy chain comprising the amino acid sequence of SEQ ID NO;

54, a first light chain comprising the amino acid sequence of SEQ ID NO;

56,

a second heavy chain comprising the amino acid sequence of SEQ ID NO;

55, and a second light chain comprising the amino acid sequence of SEQ ID NO;

57, or

(c) a first heavy chain comprising the amino acid sequence of SEQ ID NO;

58, a first light chain comprising the amino acid sequence of SEQ ID NO;

60,

a second heavy chain comprising the amino acid sequence of SEQ ID NO;

59, and a second light chain comprising the amino acid sequence of SEQ ID NO;

61, or

(d) a first heavy chain comprising the amino acid sequence of SEQ ID NO;

62, a first light chain comprising the amino acid sequence of SEQ ID NO;

64,

a second heavy chain comprising the amino acid sequence of SEQ ID NO;

63, and a second light chain comprising the amino acid sequence of SEQ ID NO;

65, or

(e) a first heavy chain comprising the amino acid sequence of SEQ ID NO;

66, a first light chain comprising the amino acid sequence of SEQ ID NO;

68,

a second heavy chain comprising the amino acid sequence of SEQ ID NO;

67, and a second light chain comprising the amino acid sequence of SEQ ID NO;

69.

20. A polynucleotide encoding the bispecific antibody of claim 1.

21. A vector comprising the polynucleotide according to claim 20.

22. A prokaryotic or eukaryotic host cell comprising the polynucleotide according to claim 20.

23. A method of producing the bispecific antibody according to claim 1, comprising the steps of a) transforming a host cell with vectors comprising polynucleotides encoding said bispecific antibody, b) culturing the host cell according under conditions suitable for the expression of the bispecific antibody and c) recovering the bispecific antibody from the culture.

24. A pharmaceutical composition comprising the bispecific antibody according to claim 1 and at least one pharmaceutically acceptable excipient.

30. A method of inhibiting the growth of tumor cells in an individual comprising administering to the individual an effective amount of the bispecific antibody according to claim 1 to inhibit the growth of the tumor cells.

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)